Venue: Rhode Island Convention Center, Providence, RI, USA
The two day WIN Symposium 2026 “Precision Oncology: Innovation and Equity Across the Globe” organized by the Worldwide Innovative Network (WIN) Consortium will take place at Rhode Island Convention Center, Providence, RI, USA on October 2-3, 2026.
Link to register coming soon!
Venue: Pennsylvania Convention Center, Philadelphia, PA, USA
We are proud to announce that the WIN Symposium 2025 has been granted endorsement by the American Society of Clinical Oncology (ASCO®) for the 14th consecutive year.
The 2025 WIN Symposium: Progress and Challenges in Precision Oncology will be presented as Track 1 of the Advancing Precision Medicine Conference in partnership with APM.
As the official 2025 WIN Symposium, this dedicated track will explore the evolving landscape of precision oncology, highlighting both groundbreaking advances and the ongoing challenges of translating molecular insights into clinical impact. Curated by the WIN Consortium, the program will feature global leaders in cancer research, diagnostics, and therapeutic innovation—offering a comprehensive view of how precision medicine is reshaping oncology across tumor types and care settings.
The symposium is co-chaired by Wafik El-Deiry, MD, PhD, FACP, Chair, WIN Consortium and Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium.
We are very proud to announce that 2019 Nobel Laureate William Kaelin, Jr, MD (Sidney Farber Professor, Harvard Medical School and Dana-Farber Cancer Institute) will be delivering the opening Keynote lecture.
For more information, visit the APM website:
https://www.advancingprecisionmedicine.com/apm-home/apm-annual-conference-and-exhibition-in-philadelphia/
The two day WIN Symposium 2024, organized by the Worldwide Innovative Network (WIN) Consortium in partnership with Burjeel Holdings, was held at the Rosewood Hotel in Abu Dhabi on March 1–2, 2024. The landmark event, themed “Precision and Molecular Oncology: Caring for Patients and Future Generations,” convened more than 450 clinicians, researchers, and industry professionals from approximately 30 countries. Together, they explored the latest advances in precision oncology and offered insights into the developments shaping the future of oncology.
The symposium started with an inspiring keynote lecture by Nobel Laureate Professor James Allison, who has revolutionized cancer immunotherapy. The curated program featured interactive elements illustrating precision cancer treatment principles and best practices.
The WIN Symposium provided attendees with a deep understanding of the role of key biomarkers, their optimal application, and emerging new omic tests that will inform future biomarker adoption under the two big umbrellas of Precision Genomics and Precision Immunotherapy. Local experience from the UAE, the host country, was included to link global evidence to regional practice. Application of the principles of precision medicine were discussed beyond medical and onto radiation oncology along with issues of access, equity and diversity in precision oncology practice and trials on a global scale. The symposium featured a Molecular Tumor Board to exemplify with real patient cases how to use biomarkers to inform therapeutic choices. Finally, a panel discussion was dedicated to navigating available diagnostic pathways and tests from bench to bedside.
The symposium provided networking opportunities, allowing participants to connect with peers, establish collaborations, and forge new partnerships.
The event was endorsed by the American Society of Clinical Oncology (ASCO®) and accredited for 8.5 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
A total of 51 abstracts were submitted—42 accepted as posters and 3 as oral presentations—with 34 featured online via the Journal of Precision Oncology (JIPO).
Cancer Care and Research in the UAE
Prof. Humaid Al-Shamsi, Burjeel Holdings
WIN Consortium: Past, Present, Future
Prof. Razelle Kurzrock, WIN Consortium/MCW Cancer Center Prof. Wafik El-Deiry, WIN Consortium/Brown University
Opening Ceremony
Keynote Lecture
Immune Checkpoint Blockade in Cancer Therapy: New Insight into Mechanisms of anti-CTLA-4, anti-PD-1, and Combination
Prof. James Allison, Nobel Laureate, MD Anderson Cancer Center
Session 2: Precision Genomics: From Bench to Bedside
Chairpersons: Prof. Garth Powis, PHusis Prof. Wafik El-Deiry, WIN Consortium/Brown University
A Visionary Odyssey Beyond Boundaries: The Evolution of Tumor-Agnostic Drug Development in Precision Medicine
Dr. Vivek Subbiah, Sarah Cannon Research Institute
Therapeutic Targeting of EMT and Tumor Plasticity
Prof. Sendurai Mani, Brown University
Role of Liquid Biopsy in Targeted Therapy
Dr. Hatim Husain, UC San Diego
The Emirati Genome Program: A National Enabler of Precision Medicine
Dr. Mohamed AlAmeri, Department of Health Abu Dhabi
Roadmap for Precision Genomics in Routine Cancer Care in the UAE
Prof. Faisal Khan, University of Calgary and OncoHelix & coLAB, Burjeel Holdings
Session 3: Precision Immunotherapy: The Next 5 Years
Chairpersons: Prof. James Allison, MD Anderson Cancer Center Prof. Padmanee Sharma, MD Anderson Cancer Center
Integrating Clinical and Laboratory Research to Identify Mechanisms of Response and Resistance to Immune Checkpoint Therapy
Prof. Padmanee Sharma, MD Anderson Cancer Center
Role of Liquid Biopsy in Immunotherapy
Prof. Christian Rolfo, Icahn School of Medicine at Mount Sinai and International Society of Liquid Biopsy [ISLB]
Transcriptomics at WIN: Opening the Multi-omic Era
Dr. Vladimir Lazar, WIN Consortium
Landscape of Immunotherapy in the UAE
Dr. Hassan Jaafar, Burjeel Medical City
Session 4: Precision Research
Chairpersons: Prof. Humaid Al-Shamsi, Burjeel Holdings Prof. Khaled Musallam, Burjeel Holdings
Landscape of Translational Cancer Clinical Trials in the UAE
Mohamed Mostafa, PDC-CRO, UAE
Oral Abstracts and Awards
Saturday, March 02, 2024
Session 5: Molecular Tumor Board
Chairpersons: Prof. Razelle Kurzrock, WIN Consortium/MCW Cancer Center Prof. Wafik El-Deiry, WIN Consortium, Brown University
Interactive Session with Cases from the UAE
Session 6: Radiation Oncology in Precision Medicine
Chairpersons: Dr. Ibrahim Abu-Gheida, Burjeel Medical City Dr. Shahin Fattahi, Burjeel Medical City
A Genomic Adjusted Radiation Dosing Paradigm to Biologically Personalize Radiation Therapy
Dr. Jacob Scott, Cleveland Clinic
Radiotherapy as Immunotherapy for Cancer
Prof. Silvia Formenti, Weill Cornell Medicine
Session 7: Precision Communityomics
Chairpersons: Prof. Wafik El-Deiry, WIN Consortium/Brown University Prof. Don Dizon, Brown University
Diversity and Equity in Precision Oncology
Prof. Don Dizon, Brown University
Tools for Precision Communityomics
Dr. Katherine Tossas, Virginia Commonwealth University
Session 8: Precision Diagnostics
Chairpersons: Dr. Alison Finall, Burjeel Medical City Dr. Pinaki Bose, University of Calgary and OncoHelix, & coLAB, Burjeel Holdings
Panel Discussion
Prof. Christian Rolfo, Icahn School of Medicine at Mount Sinai and International Society of Liquid Biopsy [ISLB] Dr. Hatim Husain, UC San Diego Dr. Helmy Eltoukhy, Guardant Health Dr. Jason Hipp, Mayo Clinic Dr. Justin Guinney, Tempus AI
JIPO and WIN renew their cooperation to cover the WIN 2024 symposium 1-2 March 2023 in Abu Dhabi, UAE.
JIPO will publish the symposium abstracts.
The WIN 2022 Symposium ‘Integrating Genomics and Transcriptomics to Reshape Precision Oncology: A WINning Strategy’ took place on 29-30 October, 2022 in Barcelona, Spain.
We had an exciting line-up of prominent speakers and panel discussion and our 1st international molecular board!
JIPO and WIN cross-promoted each other’s organization’s activities throughout the year, including the WIN 2022 Symposium in Barcelona, Spain, October 29-30, 2022. Abstracts selected for presentation at the WIN meeting were published in JIPO as a Conference Proceeding.
JIPO Editorial Fellow, Dr. Khalid Jazieh, interviewed members of WIN Leadership to highlight the collaboration and upcoming activities. Drs. Razelle Kurzrock, Vladimir Lazar, and Richard L. Schilsky were interviewed. These interviews were published on the JIPO YouTube channel.
Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN, was appointed to the JIPO Editorial Board to represent WIN Leadership. Dr. Lazar contributed to an editorial to the Journal in 2022. Dr. Kurzrock has published four articles in JIPO in 2019 and 2020.
The 11th edition of the WIN Symposia ‘WINnovation and Global Deployment of Precision Oncology’ took place in Paris, France on 23-24 June 2019.
Sunday, June 23, 2019
Welcome & Opening Remarks
Richard L. Schilsky
Lifestyle-based Prevention Strategies
Jennifer A. Ligibel
Rewriting the Code of Life: CRISPR-Cas Genome editing
Jennifer A. Doudna
Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials
Innovation in Clinical Trials: SPRING_01 Proof of Concept Trial exploring Combination of Three Targeted Drugs
Systems Immunology in IO: A view from the Parker Institute
Nikesh Kotecha
Innovative Ways of Assessing Durable Response to Immunotherapy
Christophe Le Tourneau
Monday, June 24, 2019
Direct Targeting of STAT3 Alone and in Combination with Immune Checkpoint Inhibitors to Treat Solid Tumors
David J. Tweardy
CDK4/6 Inhibitors in Breast Cancer; today's real and future dream
Hikmat Abdel-Razeq
The Value of Personalized Medicines for Healthcare Systems in Europe - Considering enablers to the adoption of personalized medicines in Europe
Anthony Barron
Development and Application of Precision Oncology in China
Hu Xin
Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations
Funda Meric-Bernstam
Oncobox, RNA Sequencing and Molecular Pathway Analysis-Based Second Opinion System for Prescription of Target Drugs to Advanced Cancer Patients: Concept, Design and Results of Clinical Trials
Anton Buzdin
Matched Tumor/Normal Expression Profiling from Small FFPE Samples
Debrah Thompson
The 10th year Anniversary edition of the WIN Symposia took place at the WIN Symposium 2018 in Paris, France on 25-26 June 2018.
The WIN Symposium Organizing Committee had chosen “Global Implementation of Precision Oncology: WINning the War against Cancer” as the theme for this celebratory event.
Monday, June 25, 2018
The TAPUR Family of Clinical Trials: Building a Global Data Sharing Platform in Precision Oncology
NCI's Integrated Precision Oncology Networks
James H. Doroshow
The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC
How Robust Are Your Archives?
Harvey I. Pass
Patients Driving Progress
Ellen V. Sigal
Tuesday, June 26, 2018
MyPathway Study: A Novel Precision Oncology Multiple Basket Trial
Mary Beattie
Precision CAR T cells Therapeutics
Carl H. June
Precision Oncology Approaches for Immunotherapy
Eric Rubin
Early development in oncology: Are the MTD and monotherapy efficiacy still the best objectives?
Giorgio Massimini, Merck KGaA
Implementing Precision Medicine in Oncology: The IMPACT Clinical Trials at MD Anderson Cancer Center
Apostolia M. Tsimberidou, UT, MDACC
The 'Greatest Hits' of Precision Oncology: the view from the newsroon
Bernadette Toner
Patients' access to Precision Oncology
Dynamic monitoring HER2 amplification of circulating DNA in metastatic colorectal cancer patients treated with cetuximab
Best Poster Award winner: Rujiao Liu et al.
The WIN 2017 Symposium with the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ was held in Paris, France, June 26-27, 2017. The overarching goal of our symposium was to share information to promote and accelerate cutting edge investigations and use of personalized, targeted cancer therapy.
Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’
ecancer Medical Science Conference Report
The WIN 2016 Symposium “Innovative Approaches to Improve Cancer Patient Outcomes”, June 27-28th was the eighth in a series of symposia dedicated to advancing personalized cancer medicine. It was a successful unique forum that brought leaders representing all stakeholders - academia, pharma, biotech / life sciences, regulatory, and health payer - together from around the globe.
Plenary Session 1: Welcome and Opening remarks:
Monday, June 27, 2016
Welcome
WIN Chairman
Patients' and Advocacy Groups Perspectives:
No innovation about us without us
Francesco de Lorenzo
Patient perspectives
Matt Ellefson
Plenary Session 2: New tools for early diagnosis, selecting therapies and monitoring:
Chairmen: Alex Drilon, Don Gibbons
Part 1: New Strategies to Improve Outcomes:
Keynote Lecture: A systems biology approach to elucidating and targeting functional tumor dependencies from patient-derived RNASeq profiles
Andrea Califano
Affordable next-generation sequencing to support therapeutic decision-making
Elaine Mardis
Part 2: Enabling Technologies: Opportunities for Liquid Biopsies:
Monitoring the cancer genome in plasma using circulating tumor DNA
Nitzan Rosenfeld
Serum miRNAs as diagnostic and prognostic tools in GI malignancies
Ajay Goel
Harnessing the biology of exosomes for diagnosis and treatment of cancer
Raghu Kalluri
Part 3: A Scientist's View of Tumor Changes under Therapeutic Pressure:
Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mCRC
Alberto Bardelli
Plenary Session 3: Innovative clinical trials to substantially improve outcome:
Chairpersons: Razelle Kurzrock, Christophe Le Tourneau
Part 1: Immune Approaches and Combinations of Targeted Therapies:
Keynote Lecture: Paths to the Curative Treatment of Cancer, ABL001: A Future Case Study?
William Sellers
Combination trial designs: How do we get efficiently to the most effective and tolerable combination regimen?
Susan Galbraith
Part 2: Right Treatment Sequencing:
Towards Using Epigenetic Therapy to Improve Cancer Immunotherapy
Daniel De Carvalho
Part 3: Forum: Is the Current Design of Precision Medicine Studies the Right One? Lessons from the Shiva Trial:
Pro Presentation
Christophe Le Tourneau
Con Presentation
Razelle Kurzrock
Plenary Session 4: Relevant models and critical preclinical data before moving to the clinic:
Tuesday, June 28, 2016
Chairmen: Alan Spatz, Brian Leyland-Jones
Keynote Lecture: Scientific wellness and cancer
Leroy Hood
Preclinical strategies for precision medicine in colorectal cancer: Challenges and opportunities
Livio Trusolino
Cancer organoids: Limiting the need for animal models?
Robert G.J Vries
Special Plenary Session:
Results of MINDACT clinical trial
Chairpersons: Martine Piccart, Thomas Tursz Suzette Delaloge
Plenary Session 5:
Expediting precision cancer medicine
Forum chaired by John Mendelsohn, Participants: Martine Piccart, Bruce E. Johnson, Amir Onn, Richard L. Schilsky, William Sellers, Josep Tabernero, Thomas Tursz, Chang Sik Yu
Plenary Session 6: Translation of big data into clinical opportunities:
Chairmen: Eitan Rubin, Yves Lussier
Part 1: Lung cancer:
Keynote Lecture: The impact of next generation sequencing on the outcomes of patients with lung cancer
Bruce E. Johnson
Part 2: Colorectal cancer:
CRC subtypes: from molecular signatures to therapeutic opportunities
Rodrigo Dienstmann
Part 3: Breast cancer:
Personalizing breast cancer therapy
Funda Meric-Bernstam
Part 4: Debate: Is big data ready to improve patient outcomes or is it a new generation of garbage in/ garbage out?:
Pro presentation/Con presentation
Yves Lussier Gordon B. Mills
The WIN 2015 Symposium, on the theme of “Novel Targets, Innovative Agents, Advanced Technologies: A WINNing Strategy?” featured a global array of many of the world’s leading experts in personalized cancer medicine - from academia, pharma, biotech, and governmental organizations.
Plenary Session 1: Opening:
Monday, June 29, 2015
Opening Addresses
WIN 2015 Keynote Opening Lecture:
The Era of Precision Cancer Medicine: A worldwide effort and challenge - Introduction to WIN Consortium
Plenary Session 2: Targeting immune mechanisms:
Monday, June 29, 2015
Chairmen: Alexander Eggermont, Robert Iannone
Keynote Lecture:
Targeting immune mechanisms
James Allison
What T-cells see on human cancer
Ton Schumacher
Plenary Session 3: Systems biology and new approaches to support personalized cancer care:
Monday, June 29, 2015
Chairmen: Thomas Tursz, Chang Sik Yu
Keynote Lecture:
A systems biology approach to precision cancer medicine
Andrea Califano
Personalized combinatorial approaches to closing down all the key oncogenic drivers
Brian Leyland-Jones
Battle-2 Trial: Mutational landscape and clinical outcome
Waun Ki Hong
Drug target activation mapping through a proteomic CLIA assay: A companion diagnostic engine for personalized medicine trials
Emanuel F. Petricoin
Plenary Session 4: Next generation of trials with targeted therapies:
Monday, June 29, 2015
Chairman: Richard L. Schilsky
Round table of pharma and academic experts
Richard L. Schilsky
WINTHER trial: Interim results and lessons learnt
Jean-Charles Soria
WINTHER trial: An SME driven EUFP7 program to create an industry standard tool to optimize therapeutic decision making
Plenary Session 5: WIN Consortium - next generation of trials with targeted therapies:
Monday, June 29, 2015
Chairmen: John Mendelsohn, Waun Ki Hong
SIMS - Simplified INterventional Mapping System for the identification of druggable activated pathways
SPRING - Rolling tri-therapy combinations of targeted drugs in second line of metastatic NSCLC
SUMMER - Elimination of relapse through innovative adjuvant targeted therapeutics in stage II and III NSCLC
Don L. Gibbons
BOOSTER - An integrative program for the discovery & validation of new blood biomarkers for NSCLC for use in early diagnosis (stage I)
Harvey Pass
Oral presentation of awarded posters
Chairpersons: Catherine Bresson, Marinus Lobbezoo
Plenary Session 6: New avenues: Big trials and big data:
Tuesday, June 30, 2015
Chairpersons: Katherine Galvin, Benjamin Neel
Keynote Lecture:
A perspective on NCI strategy and trials
James Doroshow
ASCO's initiatives in personalized medicine
New avenues for the development and evaluation of therapy
Plenary Session 7: Multi-modality and multi-drug cancer therapy:
Tuesday, June 30, 2015
Chairmen: C.S. Pramesh, Scott M. Lippman
Bottleneck problems in mutation-driven drug development and immunotherapy
Alexander M. Eggermont
Combinating radiation and immunotherapy
Ralph Weichselbaum
Plenary Session 8: Recent progress in specific tumor types:
Tuesday, June 30, 2015
Chairmen: Jean-Francois Martini, Filippo de Braud
Intrinsic subtypes of colon cancer and their response to systemic therapy
What is new in melanoma?
Iman Osman
Cancer genomics of urothelial cancer and fibroepithelial tumors of the breast
Bin T. Teh
Plenary Session 9: Regulatory and funcing challenges in the era of personalized cancer medicine:
Tuesday, June 30, 2015
Chairmen: Richard L. Schilsky, Kenneth Seamon
Keynote Lecture:
The EMA adaptive pathways approach to improve timely access for patients to new medicines
Francesco Pignatti
End points and assessment of therapeutic efficacy in personalized cancer care
Tatiana Powell
Importance of methodology certification and accreditations to perform assays
Use of targeted therapies and challenges for health payers
Carole Redding Flamm
WIN2015 - Open Forum & Closing Remarks
The WIN 2014 Symposium which was held in Paris, June 23 and 24, 2014, was an exceptional global event entirely dedicated to breakthrough biomarker investigations and combination therapies for cancer. Over 400 delegates from more than 35 countries worldwide attended the Symposium.
Opening and Welcome Addresses:
Monday, June 23, 2014
Welcome Address
WIN Consortium: Goals and strategy
John Mendelsohn, WIN Consortium
Opening Address:
Another great journey: WIN in 21st century
Trent Haywood, Blue Cross Blue Shield Association
Plenary Session 1:
Monday, June 23, 2014
Molecular analysis of immune cells and immunotherapy
Keynote Lecture:
Reinstating immunosurveillance: A prime goal of anticancer therapies and a strategic element for combination treatments
Guido Kroemer
Molecular investigations of immune cells and tumor environment: The Ovarian Cancer Model
George Coukos
Combining immunological and targeted agents: The way forward
Axel Hoos
Tumor-infiltrating immune cells as classifiers and predictors of outcome
Jerome Galon
Plenary Session 2:
Monday, June 23, 2014
What can we learn from hemato-oncology?
Keynote Lecture:
Molecular pathways in the treatment of leukemia
Bob Lowenberg
Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies
Ross Levine
Combining interferon with targeted therapeutics to eliminate leukemia propagating cells in myeloproliferative neoplasms
Eric Solary
Combination therapies in hematologic diseases
Jesus Gomez Navarro
Systems medicine approach to optimize drugs and drug combinations for individual AML patients
Olli Kallioniemi
General Discussion, Session 2
Plenary Session 3:
Monday, June 23, 2014
Innovative therapeutic initiatives and models of cooperation
Perspectives for effective cancer drug development: The EORTC SPECTA initiative
Denis Lacombe
Clinical trial designs for incorporating multiple biomarkers in combination studies with targeted agents
J. Jack Lee
General Discussion, Session 3
Monday, June 23, 2014
POSTER AWARDING CEREMONY AND PRESENTATION OF AWARDED POSTERS
Introduction Poster Award
Oral presentation Summary Poster P4.01: Somatic mutation analysis in clinical tumour samples to select patients for experimental therapies
Maider Ibarrola-Villava, et al
Oral presentation Summary Poster P5.06: Targeted delivery of a microRNA mimic as a novel approach to therapy for malignant pleural mesothelioma
Glen Reid, et al
WIN CHAIRMAN’S LECTURE:
Personalized cancer therapy: Successes and challenges
Plenary Session 3:
Tuesday, June 24, 2014
Combinations of targeted therapies (part 1)
Keynote Lecture:
Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies
Rene Bernards
Genomic complexity of metastatic disease and the conundrum of combinations
Biology driven combination therapies: How to turn up the HEAT on cancer – A PhRMA perspective
Combinations of targeted therapies in oncology – An industry view
Susan Galbraith
General Discussion, session 4
Plenary Session 4:
Tuesday, June 24, 2014
Combinations of targeted therapies (part 2)
The challenges of combinations of targeted agents in oncology
Tal Zaks
Impact of the BATTLE trial
Waun Ki Hong
Combining radiotherapy with immunotherapy in metastatic cancer
Silvia Formenti
Keynote Lecture:
Growing tissue stem cells into organoids and tumeroids: Predictive assay development
Hans Clevers
Plenary Session 5:
Tuesday, June 24, 2014
New findings on fundamental mechanisms in pediatric cancers
Keynote Lecture:
Novel drug targets and potential combinations in childhood brain tumors
Stefan Pfister
Pediatric high grade brain tumors: Epigenetic addiction of the developing brain?
Nada Jabado
WIN 2014 SPECIAL KEYNOTE LECTURE:
Cancer Stem Cells and Malignant Progression
Robert Weinberg
Plenary Session 6:
Tuesday, June 24, 2014
Blood and fluids – non-invasive investigations in oncology
Keynote Lecture:
Proactive P4 medicine-making blood a window into health and disease: A tipping point that is transforming healthcare
Circulating tumor cells (CTCs) or circulating DNA (cfDNA): What are the perspectives?
Caroline Dive
Personalized cancer medicine using the human protein atlas and affibodies
Mathias Uhlen
Wrap-up and conclusions
The WIN 2013 Symposium, held on the theme of “Personalized Cancer Medicine: From Innovation to Implementation” drew over 400 delegates from around the world. Thirty experts from academia, pharma, diagnostics, bio-informatics companies, and regulatory agencies presented and discussed their views on how new genomic and proteomic technologies and new targeted therapies affect the way individual cancer patients are treated, as well as the hurdles for implementation of personalized cancer therapy in innovative clinical trials and daily practice.
